Abstract
Interleukin-12 (IL-12) was measured in 45 asthmatic children aged 3 to 16 years. The assessments were performed on 20 children during an episode of acute exacerbation and on 25 children during remission. There was no significant difference between the mean IL-12 level during exacerbation (1.63 ± 2.08 pg/mL) and during remission (0.88 ± 0.56 pg/mL) (p = .83). A positive, but insignificant, correlation was found between forced expiratory volume in 1 second and IL-12 (p = .634). IL-12 levels were significantly lower in children with a positive family history of asthma (1.13 ± 1.78 pg/mL) compared with those without (1.31 ± 1.06 pg/mL) (p < .012), supporting the theory that the gene-environment interactions affect the immune responses. IL-12 peripheral blood levels had no detectable impact on the course of established asthma in the study population.
Highlights
IntroductionThe assessments were performed on 20 children during an episode of acute exacerbation and on 25 children during remission
Interleukin-12 (IL-12) was measured in 45 asthmatic children aged 3 to 16 years
The findings of this study demonstrated that there were no significant differences between the mean peripheral blood levels of IL-12 during asthma exacerbation and those during remission
Summary
The assessments were performed on 20 children during an episode of acute exacerbation and on 25 children during remission. IL-12 levels were significantly lower in children with a positive family history of asthma (1.13 6 1.78 pg/mL) compared with those without (1.31 6 1.06 pg/mL) (p , .012), supporting the theory that the gene–environment interactions affect the immune responses. IL-12 peripheral blood levels had no detectable impact on the course of established asthma in the study population. The main aim of the current study was to assess the relationship of IL-12 peripheral blood levels and the two states of asthma, acute exacerbation and remission, as demonstrated by the kinetics of DC activation by environmental stimuli and, Th1/Th2 polarization
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
